INCR vs. CADL, ATYR, IMMP, OLMA, KRRO, NMRA, YMAB, KOD, TVGN, and NGNE
Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Candel Therapeutics (CADL), Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), Tevogen Bio (TVGN), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry.
InterCure vs.
InterCure (NASDAQ:INCR) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
In the previous week, Candel Therapeutics had 11 more articles in the media than InterCure. MarketBeat recorded 12 mentions for Candel Therapeutics and 1 mentions for InterCure. Candel Therapeutics' average media sentiment score of 0.23 beat InterCure's score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the news media.
8.3% of InterCure shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 41.6% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
InterCure has higher revenue and earnings than Candel Therapeutics.
InterCure has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -1.25, indicating that its share price is 225% less volatile than the S&P 500.
Candel Therapeutics has a consensus price target of $19.75, suggesting a potential upside of 69.82%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than InterCure.
Candel Therapeutics received 10 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 61.90% of users gave Candel Therapeutics an outperform vote.
InterCure's return on equity of 0.00% beat Candel Therapeutics' return on equity.
Summary
Candel Therapeutics beats InterCure on 9 of the 15 factors compared between the two stocks.
Get InterCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InterCure Competitors List
Related Companies and Tools
This page (NASDAQ:INCR) was last updated on 2/22/2025 by MarketBeat.com Staff
